Experience with anti-angiogenic therapy of giant cell granuloma of the facial bones.
Interferon alfa-2a inhibits angiogenesis and was discovered through a series of laboratory experiments that began in 1980. It was first used in 1989 in the management of a child with pulmonary haemangiomatosis. Interferon alfa A was then subsequently use to treat life threatening haemangiomas and other vascular tumours in various organs. Kaban reported on anti-angiogenic therapy of a recurrent giant cell tumour of the mandible in a 5 year old girl with interferon alfa-2a reasoning that as it was a rapidly proliferating vascular lesion it could be treated as an haemangioma. This paper reviews the history and role of interferon alfa-2a as an angiogenesis inhibitor in the treatment of complex haemangiomas and presents its use in the successful management of a rapidly growing central giant cell granuloma in a 4 year old boy in Australia.
Collins
A
A
Westmead Hospital.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002675:Child, Preschool; D003937:Diagnosis, Differential; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors; D005500:Follow-Up Studies; D006101:Granuloma, Giant Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008336:Mandibular Diseases / Q000188:drug therapy* / Q000473:pathology; D008339:Mandibular Neoplasms / Q000175:diagnosis; D011994:Recombinant Proteins; D012208:Rhabdomyosarcoma / Q000175:diagnosis
D020533:Angiogenesis Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2